Barclays lowered the firm’s price target on Bristol Myers to $41 from $43 and keeps an Equal Weight rating on the shares as part of a Q2 earnings preview for the U.S. biopharmaceutical space. The analyst believes Pfizer (PFE), Eli Lilly (LLY) and Merck (MRK) “are set up for compelling updates,” while Travere Therapeutics’ (TVTX) momentum should continue into the FDA action date.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BMY:
- Ex-Dividend Date Nearing for These 10 Stocks – Week of July 1, 2024
- 2seventy Bio announces sale of Hemophilia A candidate for up to $40M
- Bristol Myers Squibb call volume above normal and directionally bullish
- Bristol Myers announces FDA accelerated approval of Krazati for CRC
- FDA approves Mirati’s Krazati sNDA for colorectal cancer